

**In The Claims**

Claims 1-29 (canceled).

30. (new) A method for treating a pulmonary disease state in mammals by protecting indigenous *in vivo* levels of nitric oxide in mammalian cells during ozone inhalation comprising contacting the mammalian cells with a therapeutically effective amount of a nitric oxide mediator, wherein the nitric oxide mediator is selected from the group consisting of pyruvates, pyruvate precursors,  $\alpha$ -keto acids having four or more carbon atoms, precursors of  $\alpha$ -keto acids having four or more carbon atoms, and the salts thereof.

31. (new) The method according to claim 30, wherein the pyruvates are selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and mixtures thereof.

32. (new) The method according to claim 30, wherein the pyruvate precursors are selected from the group consisting of pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, salts of pyruvic acid, and mixtures thereof.

33. (new) The method according to claim 30, wherein the  $\alpha$ -keto acids having four or more carbon atoms are selected from the group consisting of oxaloacetic acid, keto-glutaric acid, keto-butyric acid, keto-adipic acid, keto-caproic acid, keto-isovaleric acid, their salts and mixtures thereof.

34. (new) The method according to claim 30, wherein the precursors of  $\alpha$ -keto acids having four or more carbon atoms are selected from the group consisting of  $\alpha$ -keto acid-glycine,  $\alpha$ -keto acid-cystine,  $\alpha$ -keto acid-alanine,  $\alpha$ -keto acid-leucine,  $\alpha$ -keto acid-valine,  $\alpha$ -keto acid-isoleucine,  $\alpha$ -keto acid-phenylalanine,  $\alpha$ -keto amide, their salts and mixtures thereof.

35. (new) The method according to claim 30, wherein the disease state is selected from the group consisting of primary pulmonary hypertension, chronic obstructive pulmonary disease, adult respiratory distress syndrome, congenital heart disease, cystic fibrosis, sarcoidosis, cor pulmonale, pulmonary embolism, bronchiectasis, emphysema, Pickwickian syndrome, sleep apnea, congestive heart failure, and valvular heart disease.

36. (new) The method according to claim 30, wherein the nitric oxide mediator is present in an amount from about 0.1 millimoles to about 5 millimoles.

37. (new) The method according to claim 36, wherein the nitric oxide mediator is present in an amount from about 0.2 millimoles to about 4.0 millimoles.

38. (new) The method according to claim 30, further comprising contacting the mammalian cells with a nitric oxide source selected from the group consisting of nitric oxide, nitric oxide precursors, nitric oxide stimulators, nitric oxide donors, and nitric oxide analogs.

39. (new) The method according to claim 38, wherein the nitric oxide source is nitric oxide.

40. (new) The method according to claim 38, wherein the nitric oxide source is selected from the group consisting of L-arginine, ADP, arachidonic acid, nitroglycerin, nitroprusside, Sin-1 and SNAP.

41. (new) The method according to claim 38, wherein the nitric oxide source is present in an amount from about 10ppm to about 50ppm.

42. (new) The method according to claim 41, wherein the nitric oxide source is present in an amount from about 15ppm to about 45ppm.

43. (new) The method according to claim 38, wherein the nitric oxide mediator is administered prior to administration of the nitric oxide source.

44. (new) The method according to claim 38, wherein the nitric oxide mediator is administered concomitantly with administration of the nitric oxide source.

45. (new) The method according to claim 38, wherein the nitric oxide mediator is administered after administration of the nitric oxide mediator.

46. (new) The method according to claim 30, further comprising contacting the mammalian cells with a therapeutic agent.

47. (new) The method according to claim 46, wherein the therapeutic agent is selected from the group consisting of antibacterials, antivirals, antifungals, antitumors, antihistamines, proteins, enzymes, hormones, nonsteroidal anti-inflammatories, cytokines, and steroids.

48. (new) The method according to claim 46, wherein the therapeutic agent is administered prior to administration of the nitric oxide mediator.

49. (new) The method according to claim 46, wherein the therapeutic agent is administered concomitantly with administration of the nitric oxide mediator.

50. (new) The method according to claim 46, wherein the therapeutic agent is administered after administration of the nitric oxide mediator,

51. (new) The method according to claim 30, wherein the nitric oxide mediator is inhaled.

Prior Application  
Alain Martin  
Serial No: 10/205,353  
Filing Date: 25 July 2002  
Page 5

**RESPONSE**

Claims 1-29 of the subject application are pending in the parent application. Applicant has added new claims 30-51 and has canceled 1-29 in this continuation-in-part application. Accordingly, claims 30-51 are presently being examined.

In view of the foregoing Response, applicant requests allowance of the claims pending in this application. Applicant requests the Examiner to telephone the undersigned attorney should the Examiner have any questions or comments which might be most expeditiously handled by a telephone conference.

Applicant's attorney authorizes the Examiner to charge Deposit Account 13-4822 if there are any additional fees due in connection with this Response.

Respectfully submitted,  
Alain Martin

By   
Richard R. Muccino  
Reg. No. 32,538  
Attorney for Applicant(s)

Direct communications to:  
Richard R. Muccino  
758 Springfield Avenue  
Summit, New Jersey 07901  
voice (908) 273-4988  
fax (908) 273-4679